# EDGAR Filing Document

**Accession Number:** 0001637715
**File Stem:** 0000000000-26-004422
**Filing Date:** 2026-4
**Character Count:** 2314
**Document Hash:** 9fa38dc7cff69002e56bc5f1349378c3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-26-004422.hdr.sgml**: 20260602

**ACCESSION NUMBER**: 0000000000-26-004422

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260430

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OnKure Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001637715
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 472309515
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-295304

**BUSINESS ADDRESS:**
- **STREET 1:** 6707 WINCHESTER CIRCLE, SUITE 400
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301
- **BUSINESS PHONE:** (720) 307-2892

**MAIL ADDRESS:**
- **STREET 1:** 6707 WINCHESTER CIRCLE, SUITE 400
- **CITY:** BOULDER
- **STATE:** CO
- **ZIP:** 80301

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Reneo Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20150325
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001193125-26-177093

## Text-Extract

```

                                                           April 30, 2026

Nicholas A. Saccomano
President and Chief Executive Officer
OnKure Therapeutics, Inc.
6707 Winchester Circle, Suite 400
Boulder, CO 80301

       Re: OnKure Therapeutics, Inc.
           Registration Statement on Form S-3
           Filed April 24, 2026
           File No. 333-295304
Dear Nicholas A. Saccomano:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:    Phillip McGill

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._